For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Parion Sciences, Inc.

USPTO Granted Patents = 83

% Expired Patents = 57.8

CIPO Patents = 5

EPO Patents = 16

Forward Citations = 2,257

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Michael Ross Johnson (83 out of 170 patents)

Richard C Boucher (15 out of 52 patents)

William Robert Thelin (13 out of 13 patents)

4. Jianzhong Zhang (12 out of 344 patents)

5. Bruce Francis Molino (11 out of 41 patents)

6. Bruce Sargent (11 out of 12 patents)

7. Andrew J Hirsh (4 out of 4 patents)

8. Tomas Navratil (3 out of 11 patents)

9. Brian Button (3 out of 3 patents)

10. Ronald A Aungst, Jr (2 out of 8 patents)

11. Anthony James Hickey (1 out of 23 patents)

12. Samuel E Hopkins (1 out of 4 patents)

13. James B Fink (1 out of 25 patents)

14. Stuart Robert Abercrombie (1 out of 2 patents)

15. Mark Jeffrey Edhouse (1 out of 5 patents)

Core Competencies:

Sodium Channel Blockers

Mucolytic Agents

Aerosol Delivery Systems

Dendrimers

Pyrazinoylguanidine

Stable Blockers

Inhaled Saline

Hydration Enhancement

Epithelial Sodium Channel

Beta Agonist Activity

Phenolic Guanidine

Methods of Treatment

83 patents: Sort by Forward Citations

1. 11578042 - 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2023-02-14),

2. 10968233 - Monothiol mucolytic agents (2021-04-06),

3. 10752597 - 3,5-diamino-6-chloro-N—(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2020-08-25),

4. 10526292 - Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases (2020-01-07),

5. 10526283 - Prodrugs of dithiol mucolytic agents (2020-01-07),

6. 10335558 - Methods of treatment (2019-07-02),

7. 10246425 - 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds (2019-04-02),

8. 10233158 - Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2019-03-19),

9. 10167266 - Sodium channel blockers (2019-01-01),

10. 10159672 - Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity (2018-12-25),

11. 10106551 - Monothiol mucolytic agents (2018-10-23),

12. 10071970 - Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity (2018-09-11),

13. 9987443 - Inhaled hypertonic saline delivered by a heated nasal cannula (2018-06-05),

14. 9963427 - Dithiol mucolytic agents (2018-05-08),

15. 9957238 - Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2018-05-01),

Company Overview

Parion Sciences, Inc., based in Durham, NC, specializes in the development of innovative therapies focusing on sodium channel blockers. The company is dedicated to advancing treatment options through its expertise in mucolytic agents and aerosol delivery systems. Parion's research encompasses a range of core technologies, including dendrimers and pyrazinoylguanidine, aimed at enhancing hydration and improving respiratory health. Their commitment to scientific excellence positions them as a leader in the field of pulmonary therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

83 Patents

#14 in Durham, NC

#116 in North Carolina

#4,473 in US

#9,158 in the World

Durham, NC, United States of America

Parion Sciences, Inc.

Forward Citations = 2,257

20 inventors:

Michael Ross Johnson (83 out of 170 patents)

Richard C Boucher (15 out of 52 patents)

William Robert Thelin (13 out of 13 patents)

4. Jianzhong Zhang (12 out of 344 patents)

5. Bruce Francis Molino (11 out of 41 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Parion Sciences, Inc.. Retrieved from https://idiyas.com/company/parion-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…